Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 752.63 BATS BZX Real-Time Price As of 10:02am ET |  +15.80 / +2.14%Today’s Change | 538.01 Today|||52-Week Range 779.00 | +4.32% Year-to-Date |
Latest REGN News | Press Releases
| Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings? 7:32am / Zacks.com - Paid Partner Content | Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Jan 27 / Zacks.com - Paid Partner Content |
| Regeneron (REGN) Stock Moves -0.86%: What You Should Know Jan 30 / Zacks.com - Paid Partner Content | Covenant Asset Management, LLC Buys 3, Sells 2 in 4th Quarter Jan 24 / GuruFocus News - Paid Partner Content |
| SEIZERT CAPITAL PARTNERS, LLC Buys 3, Sells 2 in 4th Quarter Jan 30 / GuruFocus News - Paid Partner Content | Regeneron (REGN) Gains But Lags Market: What You Should Know Jan 23 / Zacks.com - Paid Partner Content |
| Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings? Jan 30 / Zacks.com - Paid Partner Content | Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023 Jan 23 / MotleyFool.com - Paid Partner Content |
| Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again Jan 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 736.83 |
| Today’s open | 750.37 |
| Day’s range | 732.43 - 752.63 |
| Volume | 3,974 |
| Average volume (3 months) | 666,118 |
| Market cap | $80.9B |
Data as of 10:02am ET, 01/31/2023
Growth & Valuation
| Earnings growth (last year) | +133.99% |
| Earnings growth (this year) | -42.95% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +89.14% |
| P/E ratio | 15.9 |
| Price/Sales | 4.41 |
| Price/Book | 4.30 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | +2.95 | +0.92% |
| ---- | ||
| ZTSZoetis Inc | -1.01 | -0.61% |
| GLAXFGlaxoSmithKline | -0.15 | -0.84% |
Data as of 10:01am ET, 01/31/2023
Financials
| Next reporting date | February 3, 2023 |
| EPS forecast (this quarter) | $10.17 |
| Annual revenue (last year) | $16.1B |
| Annual profit (last year) | $8.1B |
| Net profit margin | 50.25% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
